Correlations between calcineurin phosphatase inhibition and cyclosporine metabolites concentrations in kidney transplant recipients: implications for immunoassays.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Basic & Clinical Pharmacology & Toxicology

• Publication date

  2006-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/J.1742-7843.2006.PTO_338.XPMID 16700819
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cyclosporin

  2012cited by this paper
• Role of metabolites and calcineurin inhibition on C2 monitoring in renal transplant patients.

  2005cited by this paper
• Results of a Three-Year Prospective Study of C2 Monitoring in Long-Term Renal Transplant Recipients Receiving Cyclosporine Microemulsion

  2005cited by this paper
• RESULTS OF A THREE-YEAR PROSPECTIVE STUDY OF NEORAL C2 MONITORING IN LONG-TERM RENAL TRANSPLANT PATIENTS

  2004cited by this paper
• Validation of the calcineurin phosphatase assay.

  2004cited by this paper
• Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil.

  2003cited by this paper
• Calcineurin Phosphatase Activity and Immunosuppression. A Review on the Role of Calcineurin Phosphatase Activity and the Immunosuppressive Effect of Cyclosporin A and Tacrolimus

  2003cited by this paper
• Cyclosporine and its metabolites before and 2 h post‐dose: comparative measurements of a monoclonal and a polyclonal immunoassay

  2003cited by this paper
• Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2).

  2003cited by this paper
• Comparison of the pharmacokinetics of tacrolimus and cyclosporine at equivalent molecular doses.

  2003cited by this paper
• Review: metabolism of immunosuppressant drugs.

  2002cited by this paper
• International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group on Immunosuppressive Drug Monitoring

  2002cited by this paper
• Distribution of Cyclosporin in Organ Transplant Recipients

  2002cited by this paper
• New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine.

  2001cited by this paper
• Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients.

  2001cited by this paper
• Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.

  2001cited by this paper
• Evaluation and comparison of therapeutic monitoring of whole-blood levels of cyclosporin A and its metabolites in renal transplantation by HPLC and RIA methods.

  2001cited by this paper
• Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations.

  2000cited by this paper
• Methods for Clinical Monitoring of Cyclosporin in Transplant Patients

  2000cited by this paper
• Comparison of predose vs 2-h postdose blood metabolites/cyclosporine ratios in kidney and liver transplant patients.

  2000cited by this paper
• The temporal profile of calcineurin inhibition by cyclosporine in vivo.

  1999cited by this paper
• Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific?

  1999cited by this paper
• Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus.

  1998cited by this paper
• Cyclosporine metabolite cross-reactivity in different cyclosporine assays.

  1998cited by this paper
• Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human.

  1998cited by this paper
• Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC.

  1998cited by this paper
• THERAPEUTIC DRUG MONITORING OF CYCLOSPORINE AND TACROLIMUS

  1998cited by this paper
• Calcineurin activity in children with renal transplants receiving cyclosporine.

  1997cited by this paper
• Signaling through scaffold, anchoring, and adaptor proteins.

  1997cited by this paper
• Receptor assays in the clinical laboratory.

  1996cited by this paper
• Association of protein kinase A and protein phosphatase 2B with a common anchoring protein.

  1995cited by this paper
• Lake Louise Consensus Conference on Cyclosporin Monitoring in Organ Transplantation: Report of the Consensus Panel

  1995cited by this paper
• Methodological and Clinical Aspects of Cyclosporin Monitoring: Report of the Association of Clinical Biochemists Task Force

  1994cited by this paper
• Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines.

  1992cited by this paper
• Relative Performance of Specific and Nonspecific Fluorescence Polarization Immunoassay for Cyclosporine in Transplant Patients

  1992cited by this paper
• The clinical significance of cyclosporine metabolites.

  1991cited by this paper
• Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes.

  1991cited by this paper
• The Isolation, Structural Characterization, and Immunosuppressive Activity of Cyclosporin G (NVa2-Cyclosporine) Metabolites

  1991cited by this paper
• Cyclosporine levels together with metabolites are more effective than cyclosporine parent compound levels alone in predicting hepatic toxicity after liver transplantation.

  1991cited by this paper
• Selection of an optimal assay method for monitoring cyclosporine therapy.

  1990cited by this paper
• Clinical evaluation and therapeutic range of cyclosporine A as monitored by FPIA in kidney transplantation.

  1990cited by this paper
• Immunosuppressive activity of cyclosporine metabolites compared and characterized by mass spectroscopy and nuclear magnetic resonance.

  1990cited by this paper
• Studies on the biologic activities of Sandimmun metabolites in humans and in animal models: review and original experiments.

  1990cited by this paper
• Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine.

  1990cited by this paper
• Cyclosporine analysis by high-performance liquid chromatography: precision, accuracy, and minimum detectable quantity.

  1990cited by this paper
• Cyclosporine analysis by high-performance liquid chromatography: precision, accuracy, and minimum detectable quantity.

  1990cited by this paper
• Cyclosporine A vs cyclosporine A metabolites: comparisons of in vivo and in vitro immunosuppressive and toxic effects.

  1990cited by this paper
• Comparison of the in vitro immunosuppressive effects of cyclosporine A and its metabolites.

  1989cited by this paper
• Immunosuppressive properties of cyclosporin metabolites.

  1989cited by this paper
• Sensitivity of activated human lymphocytes to cyclosporine and its metabolites.

  1988cited by this paper
• Immunosuppressive metabolites of cyclosporine in the blood of renal allograft recipients.

  1986cited by this paper

• Development of a Physiologically Based Pharmacokinetic Model to Evaluate Dosing Regimens of Cyclosporine as a Precipitant of Organic Anion Transporting Polypeptide 1B (OATP1B)‐ and CYP3A4‐Mediated Drug–Drug Interactions

  2025cites this paper
• Dose-adjusted and dose/kg-adjusted concentrations of mycophenolic acid precursors reflect metabolic ratios of their metabolites in contrast with tacrolimus and cyclosporine

  2019cites this paper
• Cardiovascular Disease in Kidney Transplantation and Its Association With Blood Concentrations of Cyclosporine and Cyclosporine Metabolites.

  2018cites this paper
• Hydroxylated, Hydroxymethylated, Dihydroxylated, and Trihydroxylated Cyclosporine Metabolites Can Be Nephrotoxic in Kidney Transplant Recipients.

  2016cites this paper
• Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential

  2013cites this paper
• CYP3A4-mediert metabolisme av cyklosporin A i ulike mikrosommodeller : Utvikling av analysemetode for bestemmelse av metabolittene AM1 og AM9 ved UPLC-MS

  2011cites this paper
• Cyclosporine population pharmacokinetics in pediatric renal transplant recipients

  2009cites this paper
• New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation

  2009cites this paper
• EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil.

  2007cites this paper
• A review of the immunosuppressive activity of cyclosporine metabolites: new insights into an old issue.

  2007cites this paper